EU/3/15/1502

About

On 19 June 2015, orphan designation (EU/3/15/1502) was granted by the European Commission to Dr Ulrich Granzer, Germany, for trehalose for the treatment of spinocerebellar ataxia.

The sponsorship was transferred to FGK Representative Service GmbH, Germany in June 2020.

Key facts

Active substance
Trehalose
Medicine name
-
Disease / condition
Treatment of spinocerebellar ataxia
Date of first decision
19/06/2015
Outcome
Positive
EU designation number
EU/3/15/1502

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

FGK Representative Service GmbH
Heimeranstrasse 35
Schwanthalerhoehe-Laim
80339 Munich
Germany
Tel: +498989311938
E-mail: Info@seelostx.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating